SCHEMBL4516874

SCHEMBL4516874

CCOc1ccccc1CC1CCN(C2CCCCC2)C1=O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.60
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
CMA1 P23946 1/20 0.42
TP53 P04637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
GAA P10253 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
LMNA P02545 3/20 0.41
THRB P10828 1/20 0.40
TSHR P16473 1/20 0.40
C5AR1 P21730 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2989132 0.88 HSD11B1 (0.62) HSD11B1MAPTPOLBTP53ALDH1A1
SCHEMBL4499638 0.87 HSD11B1 (0.58) HSD11B1MAPTPOLBTP53ALDH1A1
SCHEMBL4509821 0.86 HSD11B1 (0.57) HSD11B1POLBTP53ALDH1A1GAA
SCHEMBL4504654 0.86 HSD11B1 (0.67) HSD11B1TP53ALDH1A1GAANPSR1
SCHEMBL4501841 0.86 HSD11B1 (0.60) HSD11B1POLBTP53ALDH1A1GAA
SCHEMBL4507235 0.86 HSD11B1 (0.52) HSD11B1MAPTPOLBTP53ALDH1A1
SCHEMBL4516967 0.85 HSD11B1 (0.56) HSD11B1MAPTPOLBTP53ALDH1A1
SCHEMBL13674424 0.85 HSD11B1 (0.53) HSD11B1TP53ALDH1A1GAANPSR1
SCHEMBL4515331 0.85 HSD11B1 (0.53) HSD11B1MAPTPOLBTP53ALDH1A1
SCHEMBL4509547 0.84 HSD11B1 (0.52) HSD11B1CMA1TP53ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885MAPT 4692/4885POLB 2628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.